Project: Original psoriasis therapies targeting the regulation of NFKBIZ

Acronym	PsoriaCure (Reference Number: 114155)
Duration	01/10/2020 - 01/04/2024
Project Topic	The project aims at providing patients with novel highly efficacious and safe drugs as well as making available highly predictive models and technologies based on the groundbreaking mode of action of our first-in-class anti-psoriasis drug candidate TEM1657. The latter is the strongest known regulator of NFKBIZ. Exploration and publication of the involved molecular and cellular mechanisms will improve the health impact of new psoriasis and other inflammatory diseases therapies.
Network	Eurostars 2
Call	Eurostars Cut–off 13

Project partner

Number	Name	Role	Country
1	PharmBioTec GmbH	Partner	Germany
2	StratiCELL Screening Technologies SA	Partner	Belgium
3	Temisis SAS	Coordinator	France
4	Université de Lorraine	Partner	France